Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
The Journal of Pathology. Clinical Research|August 23, 2023
High expression of insulinoma-associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysinAnne-Sophie Litmeyer, Björn Konukiewitz, Atsuko Kasajima, et al.Cancers|October 23, 2021
Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?Björn Konukiewitz, Atsuko Kasajima, Maxime Schmitt, et al.Clinical Epigenetics|October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification statusPhilipp Jurmeister, Karsten Weber, Sonia Villegas, et al.Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.Journal of Ovarian Research|July 31, 2023
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinomaPaul Jank, Jonas Leichsenring, Svenja Kolb, et al.International Journal of Molecular Sciences|February 11, 2023
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry ImagingJuliana Pereira Lopes Gonçalves, Christine Bollwein, Aurelia Noske, et al.International Journal of Cancer|December 20, 2021
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive diseaseAnja Kathrin Wege, Eva-Maria Rom-Jurek, Paul Jank, et al.The Journal of Molecular Diagnostics : JMD|October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic ProfilingCarsten Denkert, Marcel Romey, Brad Swedlund, et al.Signal Transduction and Targeted Therapy|March 21, 2025
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsNiklas Gremke, Isabelle Besong, Alina Stroh, et al.Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.Pageof 5